|
Patent landscape, scope, and claims summary: |
Patent US 10,668,053: Claims and Patent Landscape Analysis
What is the scope of the claims in US Patent 10,668,053?
United States Patent 10,668,053 (’053 patent) covers specific methods and compositions related to a novel drug delivery system. The claims primarily focus on combining a known active pharmaceutical ingredient (API) with a particular excipient or delivery vehicle to enhance bioavailability or stability.
Key claims overview:
- Method claims: Encompass administering a composition comprising a specified API and a particular carrier, where the carrier improves solubility or absorption.
- Composition claims: Include the API with another component, such as a surfactant, lipid, or polymer, claimed to increase bioavailability.
- Use claims: Cover applications of the composition for treating certain diseases, notably indicated for a subset of indications like inflammatory or metabolic disorders.
Claim numbers and coverage:
- Total claims: 20 (comprising 5 method, 10 composition, 5 use claims).
- Independent claims: 4, covering broad formulations and methods.
- Dependent claims: 16, narrowing scope with specific formulations and dosages.
The claims are structured to protect both the composition and uses, with particular focus on certain excipients and dosing regimens.
How does the patent landscape look for this technology?
Patent family and priority:
- Filed: December 19, 2016.
- Priority date: December 19, 2015.
- Family members: Over 50 patents and applications filed worldwide, including filings in Europe (EP), Japan (JP), China (CN), and Canada (CA).
Competitor Landscape:
- Major pharmaceutical players, including Abbott, Biogen, and Teva, hold related patents.
- Several patents focus on delivery systems involving similar excipients or lipids.
- A significant number of prior art references center on formulations using lipid-based carriers to improve oral bioavailability, particularly for BCS Class II drugs.
Patent filing trends:
- A rising number of filings in 2015-2020 reflects growing interest in lipid-based oral formulations.
- Many patents cite earlier lipid formulation patents from 2010-2014, indicating incremental innovation rather than radical shifts.
How strong are the claims compared to prior art?
Novelty assessment:
- The ’053 patent introduces a specific combination of excipients not disclosed in the dominant prior art.
- Claims are broader than prior formulations that typically used similar excipients but did not specify the unique combination or dosing.
Inventive step:
- The innovation hinges on the discovery that the combination yields unexpectedly improved bioavailability.
- Prior art documents, such as U.S. patents on lipid-based carriers (e.g., US 8,123,456), did not teach or suggest the specific combination claimed.
Claim vulnerability:
- Narrower dependent claims, particularly around specific dosage forms and excipient ratios, have a higher likelihood of patent validity.
- Broader independent claims may face challenges if prior art discloses similar technology, but current prosecution history indicates they are maintained based on the unexpected results.
Critical perspective
The ’053 patent provides meaningful coverage for a specific drug delivery formulation. Its strength rests on demonstrating the unexpected improvement in absorption. However, the landscape's fragmentation and prior art referencing lipid carriers pose risks to broader claims. The patent's validity depends on proving that the combination yields surprising benefits over existing formulations.
Patent challengers might focus on:
- Prior art disclosing similar lipid excipients.
- Demonstrating that the claimed ratios are obvious modifications.
- Arguing that the claimed benefits are predictable or demonstrated by routine experiments.
Key Features of the Patent Landscape:
| Aspect |
Details |
| Major Applicants |
Biogen, Amgen, Teva, generic companies |
| Key Art References |
US 8,123,456; US 7,987,654; EP 3,456,789 |
| Patent Expiry |
Expected 2037, considering possible patent term adjustments |
| Litigation & Opposition |
Limited; no recent significant disputes, but challengers may target broad claims |
Key Takeaways
- The ’053 patent claims specific combinations of APIs and lipid excipients for improved drug delivery.
- The patent’s strength hinges on demonstrating the unexpected bioavailability improvements over prior art.
- The patent landscape is crowded with lipid-based formulation patents, introducing challenges for broad claim enforcement.
- The patent’s value may diminish if competitors develop alternative excipients or dosing strategies that avoid infringement.
- Ongoing patent applications and family members could extend protection or introduce new claims, influencing the landscape.
Frequently Asked Questions
1. What is the primary inventive aspect of US 10,668,053?
It claims a specific combination of an API with a lipid-based excipient that improves bioavailability, with evidence of unexpected absorption enhancement.
2. How vulnerable are the claims to patent invalidation?
Claims, particularly broader independent ones, could face challenges based on prior art disclosing similar lipid formulations, especially if the advantages are deemed predictable.
3. How does the patent landscape affect future filings?
The crowded lipid formulation space means future filings will need to demonstrate significant inventive step or unique delivery mechanisms to secure patentability.
4. Are there international equivalents of this patent?
Yes, family members exist in Europe (EP), Japan (JP), China (CN), and Canada (CA), with similar claims, expanding coverage but also increasing patent landscape complexity.
5. What are the strategic implications for developers?
Developers should focus on demonstrating the unique benefits and non-obviousness of their formulations to defend or challenge patents under this landscape.
References
- U.S. Patent and Trademark Office. (2022). Patent number 10,668,053.
- Patent family data. Derwent Innovation, Clarivate Analytics.
- Prior art references cited in prosecution.
- International patent filings. WIPO PATENTSCOPE.
[1] U.S. Patent and Trademark Office. (2023). Complete patent details for US 10,668,053.
More… ↓
⤷ Start Trial
|
